Revenue Breakdown
Composition ()
No data
Revenue Streams
Sight Sciences Inc (SGHT) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Surgical Glaucoma, accounting for 99.1% of total sales, equivalent to $19.72M. Another important revenue stream is Dry Eye. Understanding this composition is critical for investors evaluating how SGHT navigates market cycles within the Medical Equipment, Supplies & Distribution industry.
Profitability & Margins
Evaluating the bottom line, Sight Sciences Inc maintains a gross margin of 88.90%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -37.20%, while the net margin is -41.04%. These profitability ratios, combined with a Return on Equity (ROE) of -57.91%, provide a clear picture of how effectively SGHT converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, SGHT competes directly with industry leaders such as SI and QTRX. With a market capitalization of $289.21M, it holds a leading position in the sector. When comparing efficiency, SGHT's gross margin of 88.90% stands against SI's 69.69% and QTRX's 42.77%. Such benchmarking helps identify whether Sight Sciences Inc is trading at a premium or discount relative to its financial performance.
